Dr. Reddy's Laboratories has reported results for fourth quarter and year ended March 31, 2022.
The company has reported a rise of 34.74% in its net profit at Rs 419.70 crore for the quarter under review as compared to Rs 311.50 crore for the same quarter in the previous year. Total income of the company increased by 10.23% at Rs 3783.40 crore for Q4FY22 as compared Rs 3432.30 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 82.59% in its net profit at Rs 97 crore for the quarter under review as compared to Rs 557.30 crore for the same quarter in the previous year. However, total income of the company increased by 15.38% at Rs 5596.80 crore for Q4FY22 as compared Rs 4850.80 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported fall of 25.76% in its net profit at Rs 1623.20 crore as compared to Rs 2186.40 crore for the previous year. However, total income of the company increased by 5.21% at Rs 14887.20 crore for year under review as compared to Rs 14150.20 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported a rise of 11.83% in its net profit at Rs 2182.50 crore as compared to Rs 1951.60 crore for the previous year. Total income of the company increased by 13.91% at Rs 22029.60 crore for year under review as compared to Rs 19338.90 crore for year ended March 31, 2021.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1620.50 |
Dr. Reddys Lab | 6171.85 |
Cipla | 1494.65 |
Zydus Lifesciences | 1013.75 |
Lupin | 1617.85 |
View more.. |